PSY27 Cost-Consequence Analysis Comparing Romiplostim to Rituximab in the Treatment of Adult Primary Immune Thrombocytopenia (Itp) in France
Nov 1, 2011, 00:00 AM
10.1016/j.jval.2011.08.999
https://www.valueinhealthjournal.com/article/S1098-3015(11)02561-7/fulltext
Section Title :
Systemic Disorders/Conditions
Section Order :
961
First Page :
A415
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(11)02561-7&doi=10.1016/j.jval.2011.08.999